News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks thought it was quite witty...lol.Nice buying today.
Ace LoL i love it
RSPI 🟢💚🚀
Nice to see RSPI close up today
Folks trying to bash down the stock?
It is the same one person bashing this stock daily.
What is his motive????
We have a lot of $$$$ invested in this stock and it a shame basher or bashers show up on company that has drugs that may provide hope for so many people. Yes all penny stocks have diluting and yes many of these stock still run hard.
This stock has a history long term history of run hard out of nowhere. I am holding and waiting.
I am still here holding a lot of shares. I got others that have been running so i just leave these idle waiting for the next run.
Other stocks that ran lately were just out of the blue and ran up.
I agree completely....
If there was ever a setup this, is it. Very low volume and PPS at depressed levels (vastly undervalued). I can point to other stocks with much higher (multiples) market caps with a fraction of the potential. All good for me and for the patient. I like getting in on bottoms. This is NOT a IHUB trading stock. This is a big money stock that will be moved by NON IHUB investors. If we haven't already been found with accumulation from weak retail selling, we soon will be imho.
As much as many would not like to hear this. When it is time, THEY WILL DECIDE when it leaves these levels. Honestly the more bashing and whining is a good sign.
Almost ALL of my biggest winners reacted this same way. Under the radar slow accumulation, folks trying to bash down a stock already beaten down to almost silliness levels with minimal volume.
Patience is key!
Agreed!
When you least expect it it will pop.
Honestly that's the best way for it to happen. When it is least expected. 👍️
I have been adding some on the dips. Holding tight. Some retail is getting shaken.
Market Cap: 697,214 (Seriously???) LOL
imho worth minimum dirt cheap at 10 million Market Cap.
That is always the case. They are all a POS until they are Not!
They will release Big News when nobody expects it.
I got my popcorn ready for RSPI!
When you least expect it it will pop.Nice buying for an uptick yesterday.
Thank You! I am holding a nice position here, but I want more! LOL I know this one is just a matter of time.
If I can get some more profits on others I will add to my position here.
I’m still here with you as well. I’m holding all the ones that I still think will pop! I’m playing crypto as well, so not as active in the pennies as I normally would be. Best of luck my friend…
Jeff is mad! Come on folks step up and average down. -J
|
Followers
|
279
|
Posters
|
|
|
Posts (Today)
|
3
|
Posts (Total)
|
45185
|
|
Created
|
12/30/04
|
Type
|
Free
|
| Moderators oldstocks DTGoody fly_fisherman jacksonjohn | |||
RespireRx Pharmaceuticals Inc. and its subsidiaries and business units are discovering and developing medicines for the treatment of psychiatric and neurological disorders, with a focus on treatments that address conditions affecting millions of people, but for which there are few or poor treatment options, including epilepsy, pain, attention deficit hyperactivity disorder (“ADHD”), recovery from spinal cord injury (“SCI”), certain neurological orphan diseases and obstructive sleep apnea (“OSA”). The RespireRx Group is developing a pipeline of new and repurposed drug products based on our broad patent portfolios for two drug platforms: (i) neuromodulators, which include GABAkines and AMPAkines, proprietary chemical entities that positively modulate (positive allosteric modulators or “PAMs”) GABAA receptors and AMPA-type glutamate receptors, respectively, and (ii) pharmaceutical cannabinoids, which include dronabinol, a synthetic compound that acts upon the nervous system’s endogenous cannabinoid receptors and
The RespireRx Group holds exclusive licenses and owns patents and patent applications or rights thereto for certain families of chemical compounds that claim the chemical structures and their uses in the treatment of a variety of disorders, as well as claims for novel uses of known drugs.
EndeavourRx: Neuromodulators
GABAkines. Under a License Agreement with the University of Wisconsin-Milwaukee Research Foundation, Inc. (“UWMRF”) and on behalf of its EndeavourRx business unit, RespireRx has licensed rights to certain selectively acting GABAkines because of their ability to selectively amplify inhibitory neurotransmission at a highly specific subset of GABAA receptors, thus producing a unique efficacy profile with reduced side effects. Preclinical studies have documented their efficacy in a broad array of animal models of interrelated neurological and psychiatric disorders including epilepsy, pain, anxiety, and depression in the absence of or with greatly reduced propensity to produce sedation, motor-impairment, tolerance, dependence and abuse. EndeavourRx currently is focusing on developing KRM-II-81 for the treatment of epilepsy and pain.
KRM-II-81 has displayed a high degree of anti-convulsant activity in a broad range of preclinical studies, including in treatment resistant and pharmaco-resistant models. Not only was KRM-II-81 highly effective in these models, but pharmaco-resistance or tolerance did not develop to its anti-convulsant properties. These latter results are particularly important because pharmaco-resistance occurs when medications that once controlled seizures lose efficacy as a result of chronic use and it is a principal reason some epileptic patients require brain surgery to control their seizures. In support of its potential clinical efficacy, translational studies have demonstrated the ability of KRM-II-81 to dramatically reduce epileptiform electrical activity when administered in situ to brain slices excised from treatment resistant epileptic patients undergoing surgery.
In addition, KRM-II-81 has displayed a high degree of analgesic activity in a broad range of preclinical studies. In intact animal models of pain, the analgesic efficacy of KRM-II-81 was comparable to or greater than commonly used analgesics. At the same time, KRM-II-81 did not display side effects such as sedation and motor impairment, but even more importantly, it did not produce tolerance, dependence, respiratory depression or behavioral changes indicative of abuse liability, which are produced by opioid narcotics and are at the heart of the opioid epidemic.
AMPAkines. Through an extensive translational research effort from the cellular level through Phase 2 clinical trials, RespireRx has developed a family of novel, low impact AMPAkines, including CX717, CX1739 and CX1942 that may have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and certain orphan indications. Our lead clinical compounds, CX717 and CX1739, have successfully completed multiple Phase 1 safety trials. Both compounds have also completed Phase 2 proof of concept trials demonstrating target engagement, by antagonizing the ability of opioids to induce respiratory depression.
AMPAkines have demonstrated positive activity in animal models of ADHD, results that have been extended translationally into statistically significant improvement of symptoms observed in a Phase 2 human clinical trial of CX717 in adult patients with ADHD. Statistically significant therapeutic effects were observed within one week. We believe AMPAkines may represent a novel, non-stimulant treatment for ADHD with a more rapid onset of action than alternative non-stimulants, such as Straterra® (atomoxetine), and without the drawbacks of amphetamine-type stimulants.
In a series of important studies funded by grants from the National Institutes of Health and published in a number of peer reviewed articles, Dr. David Fuller (University of Florida), a long-time RespireRx collaborator, has demonstrated the ability of CX1739 and CX717, RespireRx’s lead AMPAkines, to improve motor nerve activity and muscle function in a number of animal models of spinal cord injury (SCI).
| FORM TYPE | RECEIVED | PERIOD END DATE | REPORT |
|---|---|---|---|
| 8-K | 02/02/2024 | 01/30/2024 | PDFRTFHTMLXLS |
| 8-K | 01/22/2024 | 01/18/2024 | PDFRTFHTMLXLS |
| 8-K | 12/11/2023 | 12/06/2023 | PDFRTFHTMLXLS |
| 10-Q | 11/17/2023 | 09/30/2023 | PDFRTFHTMLXLS |
| NT 10-Q | 11/14/2023 | 09/30/2023 | PDFRTFHTML |
| 8-K | 10/12/2023 | 10/09/2023 | PDFRTFHTMLXLS |
| 8-K | 10/02/2023 | 09/26/2023 | PDFRTFHTMLXLS |
| 10-Q | 08/21/2023 | 06/30/2023 | PDFRTFHTMLXLS |
| NT 10-Q | 08/14/2023 | 06/30/2023 | PDFRTFHTML |
| 8-K | 08/09/2023 | 08/03/2023 | PDFRTFHTMLXLS |
DISCLAIMER:
Nothing in the contents transmitted on this board should be construed as an investment advisory, nor should it be used to make investment decisions.
There is no express or implied solicitation to buy or sell securities.
The author(s) may have positions in the stocks or financial relationships with the company or companies discussed and may trade in the stocks mentioned.
Readers are advised to conduct their own due diligence prior to considering buying or selling any stock.
All information should be considered for information purposes only.
No stock exchange has approved or disapproved of the information here
